FORT LEE, N.J., Sept. 26 /PRNewswire-FirstCall/ -- Alpharma Inc. , a global specialty pharmaceutical company, announced today that the Circuit Court of Washington County, Arkansas, Second Division, today ruled in the company’s favor in litigation involving roxarsone, a product sold by Alpharma’s Animal Health division. The plaintiffs in the case alleged that exposure to chicken litter containing certain residue from the company’s product caused a form of leukemia in one of the plaintiffs. The jury in this case found that the plaintiffs did not meet the burden of proof, and therefore found Alpharma not liable for the illness suffered by the plaintiffs. The plaintiffs have the right to appeal the court’s decision.
This is the first trial in this matter, in which approximately 175 plaintiffs are seeking personal injury damages in connection with exposure to residue from the company’s product. The company expects a second trial to commence in April 2007.
Alpharma press releases are also available at our website: http://www.alpharma.com.
Alpharma Inc. is a global specialty pharmaceutical company with leadership positions in products for humans and animals. Alpharma is presently active in more than 60 countries. Alpharma has a growing branded franchise in the chronic pain market with its morphine-based extended release KADIAN(R) product. In addition, Alpharma is among the world’s leading producers of several specialty pharmaceutical-grade bulk antibiotics and is internationally recognized as a leading provider of pharmaceutical products for poultry and livestock.
Alpharma Inc.
CONTACT: Kathleen Makrakis, Investor Relations, +1-201-228-5085,kathleen.makrakis@alpharma.com
Web site: http://www.alpharma.com/
